OncoSec Medical News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.05.23	OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire)
16.05.23	OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire)
16.05.23	OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program (PR Newswire)
27.04.23	OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program (PR Newswire)
11.04.23	OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire)
10.04.23	OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire)
03.04.23	OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment (PR Newswire)
03.03.23	Pre-market Movers: BFRG, VERU, ARDX, GMVD, RKDA… (RTTNews)
01.03.23	Pre-market Movers: RETA, ONCS, LION, NVAX, SRPT… (RTTNews)
05.12.22	OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022 (PR Newswire)
30.11.22	OncoSec Announces Pricing of $3.5 Million Public Offering (PR Newswire)
30.11.22	Pre-market Movers: HZNP, RVP, SFR, TMDX, CRWD… (RTTNews)
17.11.22	Pre-market Movers: ARDX, GRTX, BBWI, PXMD, TNYA … (RTTNews)
15.11.22	OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma (PR Newswire)
11.11.22	OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment (PR Newswire)
08.11.22	OncoSec Announces Reverse Stock Split (PR Newswire)
05.10.22	OncoSec Medical To Reduce Staff By About 45% (RTTNews)
04.10.22	OncoSec Announces Pipeline Prioritization and Workforce Reduction (PR Newswire)
24.06.22	Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research (PR Newswire)
23.05.22	OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research (PR Newswire)
29.04.22	OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer (PR Newswire)
22.02.22	OncoSec Announces Appointment of George Chi as Chief Financial Officer (PR Newswire)
17.12.21	OncoSec Announces Changes to its Board of Directors (PR Newswire)
02.11.21	OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study (PR Newswire)
20.10.21	OncoSec Provides Business Update (PR Newswire)
16.08.21	OncoSec Provides Leadership Update (PR Newswire)
26.07.21	OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference (PR Newswire)
06.07.21	OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma (PR Newswire)
24.06.21	OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer (PR Newswire)
14.06.21	OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering (PR Newswire)
24.11.20	OncoSec Secures Rights For Cliniporator Gene Electrotransfer Platform Developed By IGEA (RTTNews)
08.11.20	Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing (RTTNews)
06.05.20	OncoSec's TAVO-KEYTRUDA Shows 41% ORR In Late-Stage Metastatic Melanoma Study (RTTNews)
11.10.19	5 Top Gainers In Healthcare Sector (RARX, ONCS, MREO…) (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu OncoSec Medical Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten